KIROMIC BIOPHARMA INC (KRBP)       0.2299  -0.01 (-4.29%)

0.2299  -0.01 (-4.29%)

US4976341051 - Common Stock


Fundamental Rating

1

Taking everything into account, KRBP scores 1 out of 10 in our fundamental rating. KRBP was compared to 637 industry peers in the Biotechnology industry. KRBP has a bad profitability rating. Also its financial health evaluation is rather negative. KRBP is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

1

KRBP has a Piotroski-F score of 4.00. This indicates an average health and profitability for KRBP.
The profitability ratios for KRBP are negative, so there is not much use analyzing them.

KRBP has a Return On Assets of -166.81%. This is below the industry average of -44.55%. 92% of the industry peers outperform KRBP.
VS Industry

ROA (-166.81%) VS Industry: 8% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

3

When comparing the current price to the book value of KRBP, it is valued rather cheaply. It is trading at 0.36 times its book value.
When comparing the price book ratio of KRBP to the average industry price book ratio of 1.69, KRBP is valued rather cheaply. KRBP is also cheaper than 90% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 1.08, KRBP is valued rather cheaply. On top of this, KRBP has a better ratio than 95% of the companies listed in the same industry.

The Price/Earnings Ratio is negative for KRBP. In the last year negative earnings were reported.
Also next year KRBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.36) VS Industry: 90% outperformed.

138.52
0.09

Enterprise Value/ EBITDA (0.06) VS Industry: 95% outperformed.

3,199.01
0.01

Growth

Growth Rating

0

KRBP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.52%.

The Earnings Per Share is expected to decrease by -0.75% on average over the next 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -3.52% -8.04% -9.13% 0% -0.75%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

2

A Current Ratio of 1.35 indicates that KRBP should not have too much problems paying its short term obligations.
A Quick Ratio of 1.35 indicates that KRBP should not have too much problems paying its short term obligations.
The Debt to Equity ratio of KRBP is in line with the industry averages.
KRBP has a Piotroski-F score of 4.00. This indicates an average health and profitability for KRBP.

Compared to an average industry Current Ratio of 6.11, KRBP is worse placed to pay its short term obligations than its industry peers. 91% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.02, KRBP is worse placed to pay its short term obligations than its industry peers. 90% of its industry peers have a better Quick Ratio.
KRBP has an Altman-Z score of -10.90. This is a bad value and indicates that KRBP is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of KRBP to the average industry Altman-Z score of -0.62, KRBP is less financially healthy than its industry peers. 84% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (1.35) VS Industry: 10% outperformed.

0.02
84.53

Current Ratio (1.35) VS Industry: 9% outperformed.

0.02
85.09

Altman-Z (-10.9) VS Industry: 16% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

KRBP does not give a dividend.

KRBP Daily chart

KIROMIC BIOPHARMA INC0.2299

NASDAQ:KRBP (12/8/2022, 7:00:02 PM)-0.01 (-4.29%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-12 2022-08-12/amc Earnings (Next) 03-09 2023-03-09
Ins Owners 6.56% Inst Owners 1.68%
Market Cap 4.19M Analysts N/A
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.36
EV/EBITDA 0.06
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -3.52% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 20.59%
EPS Next Y -8.04% EPS Next 2Y -9.13%
EPS Next 3Y 0% EPS Next 5Y -0.75%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 1.35 Quick Ratio 1.35
Altman-Z -10.9 F-Score 4
Debt/Equity 0 WACC N/A
ROIC/WACC N/A
Profitability
ROA -166.81% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA